Member Info for Chelsea11

Thanks CW and contains the RNS statement from Lindy, which links to any funding related convo.

“We remain one of only a few companies worldwide that has the capability to produce high affinity, humanised anti-glycan antibodies and continue to evaluate options and potential agreements for the Company's GlyMab® antibodies in order to provide further third-party validation, develop the business and generate revenues.”

Tiny Scancell. One of the few companies worldwide.

Not quite the apocalypse.

More a car park trolley dent.

Dark Prince 08:30 this morning.

“When this falls below 20p let me know if this is not a dull RNS”

Right-o

Hey Chester. Your enthusiastic, historic post pasted earlier by AB, far outweighs his/her repeated negative spin imo. I didn’t take your post at that time to mean everyone’s tumours were melting, as I would have been foolish to do so. Am sure that applies to anyone with a bit of sense. Apologies from me though, for unwittingly dredging up your post.

AB - who specifically said that please?

No flannel - who?

50 trades and the end of the world is nigh :-)

Compare the content with 2021 Interims. It’s crystal clear (to me) that the company has taken a big leap forward in those 12 months. Will they do that again in the next 12 months - place your bets.

Wild - normal.

But I agree there’s a built in Get Out Of Jail Free card ;-)

Major players will of course be fully aware. Like any other industry, they employ people specifically to watch the competition.

Violin, of course you might be right. I'd be pretty disappointed though if we're now moving sights towards the end of Q1!

Don't think I'd be alone there.

Have suggested a couple of times that the Interims will include Post Period Updates - am sure most would expect that. What is to stop those updates from being significant / comprehensive , given a) it would be being delivered via formal RNS and b) the RNS could be titled accordingly ie. Interim Results + xxxxxxxxxx (fill in the blanks).

Not suggesting that’s the best way before anyone take it off at that tangent and the point is lost. Just raising the possibility and of course we may yet see a standalone RNS outside of the Interims.

I guess you can lift and interpret what you want from that Presentation (and any other).

For instance……….

“Vaccine portfolio has multiple near-term value inflection points”

Yes and we’re guaranteed at least one RNS next week. That may contain all manner of poet-period updates, if it turns out nothing separate is sent (which it may).

Clearly a week to look forward to. News is coming one way or another.

HAGW all.

I saw a big stretch white limo going down the road earlier today.

That must surely be a good omen :-)

And ahead of that, perhaps a positive impact on the SP generated by FOMO.

Best of luck everyone.

Well, she who must be obeyed wants a new sparkler (again), so I'm hoping you're right.

Of course any more fireworks jokes, would be bang out of order.

Berm - although the Genmab payment was received post 31/10, isn’t it still a possibility that it could be confirmed in the forthcoming Interim Results as a post-period item? This has happened in the past and from memory, one example was the Redmile funding.

Not saying it will be there but shouldn’t be ruled out?

I think a fair point from Violin around the wording of this years Notice. If you look at the previous one (Dec 21), you can see how it is framed very differently.

Not myself suggesting anything sinister in that but was a fair observation.

This lack of news won’t last furlong.

The only link I want to click on this, or next week, is to some news actually driven from Scancell.